Abstract PR078/#804 Table 1
Megace (N=16)
Mirena (N=15)
3-month regression N,(%)
6 (37.5)
9 (60.0)
6-month regression N,(%)
12 (75.0)
12 (80.0)
9-month regression N,(%)
14 (87.5)
13 (86.7)
Persistence N,(%)
1 (6.3)
2 (13.3)
Cancer N,(%)
1 (6.3)
0 (0%)